Search

The biopharmaceutical company reaffirms its commit.

Meet Balder, our new ally. We talked to Óscar García, founder partner.

The 2024 program application will open on January 25th and close on February 21st.

This is evident in the study conducted by EuropaBio, titled "Impact of the General Pharmaceutical Legislation of the European Union on the Innovation Ecosystem and Biotechnological Companies in Europe

The catalog, which currently includes 672 tests, will continue to be progressively expanded due to its 'flexible' nature, with the commitment to ensure more homogeneous and equitable access to these

The letter is supported by 35 Nobel laureates and over 1,000 scientists, urging the European Parliament to unlock the use of New Genomic Techniques in agriculture.

PreveCol®, a blood test for oncological diagnosis, has obtained US recognition for its efficacy in detecting precancerous lesions compared to existing alternatives in the United States.

Meet BIOXYTOL, our new member. We talked its with Kamaljit S. Sood, CEO.

Meet THYTECH, our new member. We talked to its Rafael Correa-Rocha, Director & Co-Founder.

The event will feature a brief review of the topline results of the Phase IIb PORTICO study, then a discussion with experts.

The technical meeting and collaborative forum have been held under the title "Applications of non-viral vectors in gene editing and therapy: Challenges for academia and industry."

This initiative aims to have a positive long term impact on the environment, economy and society by helping achieve 10 of the Sustainable Development Goals (SDG).

January 10th, in an event with numerous institutional representatives, headed by the Lehendakari Iñigo Urkullu, together with representatives from the business, financial, scientific-technological and

The Investor Day, organized by AseBio and positioned as the benchmark meeting between investors and Spanish biotech companies, will take place on May 15th.

Innovation has enabled breakthroughs such as recent drugs for Alzheimer's disease, the use of devices that stimulate brain function for the treatment of certain pathologies or Virtual Reality for post

Funding will Support Development of AI Clinician, Using Spatial Computing.

AseBio has been a key player in the journey taken over these 25 years by biotechnology in Spain, positioning itself as a strategic agent in the face of challenges and future prospects.

The objective of this study was to analyze the impact of glaucoma in ambulatory centers and hospitals in Spain over the past decade and to measure the associated direct medical costs and incidence.

Due to Spain's scientific and technological potential, both in the public and private sectors, our country has the responsibility to give a new boost to the biotechnological sector and thus respond to

Results across all efficacy endpoints consistently favored vafidemstat over placebo. Global Statistical Test (GST p-values) confirms consistent trend across efficacy endpoints.